the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
Published 3 months ago • 65 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
1:24
the promising role of pacritinib for the treatment of patients with mf and severe thrombocytopenia
-
1:21
pacifica: phase iii study of pacritinib vs bat in patients with mf and severe thrombocytopenia
-
58:28
peripheral blood film evaluation: a critical component of a complete blood count (cbc)
-
1:53:59
the pathophysiology of itp and novel therapies
-
14:40
primary myelofibrosis (pmf)
-
2:05
investigating the efficacy of tp-3654 in patients with myelofibrosis: results from phase i study
-
1:42
consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
1:49
approved and emerging agents to manage anemia and thrombocytopenia in myelofibrosis
-
2:28
investigating the impact of pacritinib on survival in patients with mf and severe thrombocytopenia
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
1:38
phase ii trial of luspatercept in myelofibrosis-associated anemia
-
4:14
long-term safety and efficacy of sutimlimab for chronic itp
-
1:06
origins and treatment options for anemia in myelofibrosis
-
3:05
ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis